Immunocore Publishes Presentation on Phase 1 Brenetafusp Study in Metastatic Uveal Melanoma

Bitget2026/11/07 22:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunocore published a Phase 1 presentation evaluating brenetafusp alone or with tebentafusp in metastatic uveal melanoma.
The first-line combination cohort of 17 patients achieved a 29% response rate; median progression-free survival was 8.1 months.
Two-year overall survival reached 70%, with median survival follow-up of 29 months.
Combination treatment showed no new safety signals; no treatment-related adverse events caused discontinuation or death across either treatment group.
The findings support further evaluation in DUET-UVEAL, a randomized Phase 2/3 study in planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunocore Publishes Presentation on Phase 1 Brenetafusp Study in Metastatic Uveal Melanoma

You may also like

Crypto prices